The call featured a presentation and discussion by Key Opinion Leaders (KOLs) Damen Reed, MD (Moffitt Cancer Center) and Jonathan Whetstine, PhD (Fox Chase Cancer Center) who discussed Epigenetics, and how drugs that require gene expression ("epigenetics drugs") are a viable strategy for treatment and management of cancer.
You can hear a recording of the discussion Here
They also discussed recent clinical successes with epigenetic drugs and what to expect from novel agents.
The meeting opened with a presentation by Salarius' CEO, David Arthur and Senior Medical Advisor, Margaret Dugan, MD providing an update on their lead program, Seclidemstat. Management shared the latest on their clinical program and on new areas of interest including immunotherapy and select tumor mutations. Seclidemstat, a reversible LSD1 inhibitor, inhibits LSD1's enzymatic and scaffolding properties, representing a viable therapeutic option for patients who need it the most.
Recent White Paper: Salarius - An Epigenetic - Focused Oncology Company
About Salarius: Salarius (NASDAQ: SLRX) is a clinical-stage oncology company targeting the epigenetic causes of cancers. Salarius recently completed a reverse merger and is an exciting new public company with a differentiated lead drug candidate in the hot epigenetic space. The company’s lead candidate, Seclidemstat, is a differentiated inhibitor of the LSD1 epigenetic enzyme. Seclidemstat is a more comprehensive inhibitor of LSD1’s scaffolding and enzymatic properties when compared to the competition. Salarius believes that Seclidemstat’s differentiated binding mechanism and location within LSD1 may lead to improved safety and efficacy compared to other LSD1-targeted therapies in clinical development.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as “will,” “can,” “believe,” ”plan,” “allow,” “expect,” “provide,” “able to,” “position,” “hope” and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements relating to the following: the company’s belief that the stock purchase agreement will provide additional access to capital and financing flexibility to allow the company to continue to execute its clinical plans and further advance its lead drug candidate, Seclidemstat, creating value for its shareholders; the anticipated use of proceeds from the agreement; the company’s belief that it is well funded, ultimately driving value for its shareholders; expectations regarding Aspire Capital’s future hold of the company’s common stock, including the timing of any sale; expectations regarding future sales to Aspire Capital under the agreement, if any; expected timing and results of clinical studies and delivery of clinical milestones in 2020, including the company’s expectations on reaching maximum tolerated dose early 2020 and reporting early patient data later in the same year; Seclidemstat’s potential benefits to patients and their families and the company’s potential to bring hope and new treatments for patients and their families; the nature, strategy and focus of the company; and the development and commercial potential of any product candidates of the company. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the ability of the company to raise additional capital to meet the company’s business operational needs and to achieve its business objectives and strategy; the company’s ability to project future capital needs and cash utilization; future clinical trial results; that the results of studies and clinical trials may not be predictive of future clinical trial results; the sufficiency of Salarius’ intellectual property protection; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; market conditions which may impact the ability of Salarius to sell stock to Aspire Capital; the possibility of unexpected expenses or other uses of Salarius’ cash resources; and other risks described in Salarius’ filings with the Securities and Exchange Commission, including those under the heading “Risk Factors.” The forward-looking statements contained in this press release speak only as of the date of this press release and are based on management’s assumptions and estimates as of such date. Salarius disclaims any intent or obligation to update these forward- looking statements to reflect events or circumstances that exist after the date on which they were made.